key: cord-0825744-74v04jmb
authors: Milks, M. Wesley; Sahay, Sandeep; Benza, Raymond L.; Farber, Harrison W.
title: Risk assessment in patients with PAH in the era of COVID-19 and the telehealth revolution
date: 2020-12-19
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2020.12.005
sha: 17cb0e2ae6598c937f26d9c82310a2eed6a5e2d0
doc_id: 825744
cord_uid: 74v04jmb

Patients affected by pulmonary arterial hypertension (PAH) benefit from intensive, continuous clinical monitoring to guide escalation of treatments that carry the potential to improve survival and quality of life. During the COVID-19 pandemic, the need for physical distancing has fueled the expeditious expansion of various telehealth modalities, which may apply in a unique manner to individuals with PAH. Performance of objective risk assessments in patients with PAH remotely via telemedical visits and other telehealth mechanisms is unprecedented and not yet rigorously validated. The uniquely high risk for rapid deterioration in PAH patients demands a high degree of sensitivity to detect changes in functional assessments. In this review, several telehealth modalities for potential utilization in risk assessment and treatment titration in patients with PAH are explored, yet additional study is needed for their validation with the pre-pandemic care paradigm.

The COVID-19 pandemic has posed unprecedented challenges in the management of patients with chronic diseases. Patients with pulmonary arterial hypertension (PAH) need close monitoring and serial evaluation, given their high risk for rapid deterioration, identification of which can trigger timely treatment intensification that attenuates disease progression. COVID-19 has adversely influenced the care of many PAH patients, especially during periods in which 'stay at home' policies may decrease a patient's confidence in the safety of an in-person visit.

During such times, many PAH expert centers have adopted telemedical tools to evaluate these potentially complex patients. Prior to the emergence of COVID-19, telehealth comprised an important but generally non-dominant role in ambulatory health care. With the onset of the pandemic, the essentially instantaneous necessity of providing telehealth services to preserve physical distancing has opened the (virtual) "door" for remote health care access for many PAH patients. While 'telemedicine' is generally used to refer to virtual visits with a health care provider 1 , the term 'telehealth' may be more broadly defined as "technology-enabled health care management and delivery systems that extend capacity and access" 2 . Telehealth also encompasses use of mobile technologies to support maintenance of health and wellness, sometimes termed 'mHealth'. To the authors' knowledge, no study yet has demonstrated effectiveness of the use of telehealth services to improve outcomes specifically in PAH patients. Individuals affected by PAH rely on a uniquely aggressive multimodality evaluation at each point of health care contact to assess for any subtle worsening of the disease.

Current practice in management of PAH patients requires ongoing reassessment for risk of disease progression based on multiple types of data including reported functional capacity, six-minute walk test (6MWT) results, serum brain natriuretic peptide, and echocardiographic findings. Guidelines founded on the current body of evidence direct that that each PAH patient undergo objective risk assessment during each office visit [3] [4] [5] [6] [7] . While telemedical video visits (VV) with providers may deliver ambulatory care as definitive in quality as an in-person visit for a variety of conditions, the ways in which the spectrum of telehealth services can meet the distinctive needs of PAH patients has yet to be fully elucidated. In this review, several currently available telehealth modalities that can be utilized in the remote assessment of PAH patients are explored, with recognition of the need for intensive further study to define and validate an optimal approach in this important population.

COVID-19 has brought unprecedented challenges to healthcare, especially in the management of chronic diseases like PAH, which is often associated with delayed diagnosis 8 . and, once diagnosed, warrants close monitoring. A recent study showed that during the mandated 'lockdown' period, there was close to a 50% decline in new appointments for PAH evaluation, with similar reduction in the initiation of PAH specific therapy, when compared with prior seasonally adjusted data 9 . Qaiser et al. 10 recently discussed safety precautions for performing right heart catheterization for PAH evaluation during this oandemic. Another study evaluated a combination of three echocardiographic parameters including left atrial size, E:e' ratio, and presence of systolic interventricular septal flattening in discriminating PH due to left heart disease vs. PH due to a pulmonary vascular process 11 . The authors suggested that this information can be obtained from a routinely performed echocardiography; this may abrogate the need for travel for another echocardiogram dedicated for assessment of PAH.

Just as the diagnosis of PAH can be adversely impacted during the COVID-19 pandemic, so can the implementation of therapy. A recent survey from U.S. PAH expert centers showed a hospitalization rate of 30% and mortality of approximately 12% in PAH or chronic thromboembolic pulmonary hypertension (CTEPH) patients infected with COVID-19 12 . This survey also demonstrated fewer clinic visits and increased use of telemedicine in PAH patients, as well as decreased diagnostic testing in individuals suspected of PAH.. Delayed referral, compounded with delayed assessment, has clear potential to harm the overall outcome of PAH patients. Notably, the 12% mortality rate from COVID-19 among PAH/CTPEH patients reported from this survey appears higher than that of the general population 13 . In contrast, in a recent commentary, Horn E et al. 14 speculated that PAH might be beneficial in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to protection provided by endothelin receptor antagonist (ERA) therapy, which blocks the same angiotensin-converting-enzyme 2 (ACE2) receptor needed for SARS-CoV-2 viral entry into the cell. Yet, critics of this hypothesis contend that it may provide false reassurance to PAH patients who are at higher risk of poor outcomes 15 . Recent reports of COVID-19 infection affecting the pulmonary vasculature and right ventricle are intriguing, but the long-term impact of COVID-19 on PAH disease progression and outcomes has yet to be established.

Use of telehealth services between provider visits has been widely explored in cardiovascular conditions. While findings are generally auspicious, evidence of benefit is not uniform across prior studies of telehealth interventions in heart failure (HF), which raises concern regarding the generalizability of such interventions. Where promising evidence exists, there are logistical challenges to broad-scale implementation due to barriers in the translation of telehealth strategies into practice. In 2010, Inglis et al. published a meta-analysis of randomized controlled trials comparing structured phone support and/or noninvasive telemonitoring with usual care of patients with HF 16 . Noninvasive telemonitoring interventions entailed objective review of blood pressure, weight, electrocardiograms, or rhythm strips. In this meta-analysis, both interventions resulted in a significant reduction in HF-related hospitalization. Telemonitoring reduced allcause mortality (RR 0.66, 95% CI 0.54 to 0.81, P<0.0001) but phone-based support demonstrated no definite effect (RR 0.88, 95% CI 0.76 to 1.01, P=0.08).

Subsequently, the Telemonitoring to Improve Heart Failure Outcomes (Tele-HF) trial randomized patients recently hospitalized with exacerbated HF to a telephone-based interactive voice-response system that collected daily information about symptoms and weight, the results of which were reviewed by clinicians, vs. usual care 17 . This showed no significant difference between the intervention and usual-care groups with respect to all-cause readmission or death within 180 days. Similarly, the Better Effectiveness After Transition-Heart Failure (BEAT-HF) randomized clinical trial assessed the effectiveness of pre-discharge education, systematized telephone calls, and remote telemonitoring among patients hospitalized for HF across 6 academic medical centers in California 18 . Wireless electronic devices were used to transmit daily data, including patient blood pressure, heart rate, and weight to a nurse triage center, triggering a nurse response if clinical attention was required on the basis of pre-defined parameters. The trial failed to show improvement in all cause hospitalizations or mortality, but secondary analysis suggested improvement in 180-day quality of life scores due to the intervention. Another meta-analysis and systematic review by Feltner et al. examined 47 trials that employed telemonitoring services, phone-based support interventions, as well as home-visiting programs intended to prevent read-missions in patients with HF 19 . In composite, structured phone-based interventions reduced HFspecific readmission and mortality, yet telemonitoring failed to improve 30-day readmission or 3 to 6-month all-cause readmissions.

Despite a lack of uniformity, the aforementioned studies based on remote "check-ins" and/or periodic vital sign telemonitoring between provider visits do support potential benefit of these approaches in individuals with cardiovascular diseases such as HF. Continuous monitoring strategies including accelerometry and invasive pulmonary artery pressure measurement have been applied to PAH patients and are discussed subsequently. Accelerometry devices (e.g. Ac-tiLife, ActiGraph, LLC, Pensacola, FL) have been studied in PAH patients, noting their potential 23 . Portable impedance cardiography devices have also been applied to describe heart rate changes over time during the 6MWT in PAH patients vs. healthy controls 24 .

While noninvasively assessed biometric and accelerometric data are obtained with relative ease, invasive monitoring such as the CardioMEMS HF system (Abbott), an implantable pulmonary artery pressure monitor, has also generated considerable interest among those who care for individuals with PAH. The key concept supporting the utility of this device is that measurable and actionable filling pressure elevations may long precede clinical decompensation 25 (Figure 1 ). Among 26 patients with PAH and NYHA Class III or IV HF, the Cardi-oMEMS HF System was safely used to monitor PAH therapy, with no apparent device-related serious adverse events 26 . Using trends of CardioMEMS HF device-generated data, the study showed significant reduction in pulmonary artery pressure and improved cardiac output as early as one-month postimplant ( Figure 2 ). The study also showed significant improvement in functional class and quality of life scores within one year. Among other invasive devices, implantable loop recorders, which are widely used for arrhythmia detection, are under study for specific application to a HF population (e.g. Reveal LINQ, Medtronic, Dublin, Ireland) 27 .

Overall, telehealth services have demonstrated variable success in the management of chronic HF between visits with health care providers. However, such study is lacking yet critical in PAH management in the era of COVID-19, the success of which depends on the quality and depth of clinical and biometric information gathered.

A video visit (VV) is a synchronous communication between a patient and health care provider utilizing technology that provides real-time, 2-way audio and visual interaction. Telecommunication platforms may be integrated within the electronic health record, third-party business-oriented videoconferencing mechanisms, or medically-optimized solutions touting HIPAAcompliance, some with the option for the patient to initiate the interaction by responding to a text message invitation (e.g. Updox, Doximity Dialer Video, Doxy.me). Prior to the COVID-19 pandemic, such VVs were already a viable method for performing ambulatory office-based care remotely, particularly in the period following hospital discharge, with a trend toward lower noshow rates compared to traditional visits among HF patients 28 . Virtual VVs are also demonstrably effective among Veterans Affairs patients 29 . In fact, the VA has served as a key pioneer for telehealth advancements well prior to the COVID-19 era. In general, many patients find VV convenient and appreciate access to their providers without having to incur risk of viral exposure associated with travel or presence in a health care facility. Contrarily, some patients voice valid concerns regarding lack of a hands-on physical examination. Yet, health care providers learn much from observing the general appearance and behavior of the patient and may still capture certain findings such as the skin exam, including the appearance of wounds, catheter sites, device implant incisions, extremity swelling, or rashes, as well as breathing patterns and physical movement. A recent study compared the remote assessment of jugular venous pulsation (JVP), an arguably essential part of the physical examination of a PAH or HF patient, to the bedside assessment of JVP in patients with systolic left heart failure 30 . The study showed that bedside and remote JVP estimates were comparable (R 2 = 0.635) and significantly correlated with invasively measured RAP, despite a lower level of confidence among the remote evaluators in their estimates. Yet, this level of confidence may have been simply due to decreased familiarity with the process of remote evaluation.

Telemedical exams may also supply information not readily available during in-person office visits, such as views into the patient's home environment (if the patient agrees to share this), including physical barriers that could increase the risk of falls such as stairs or imposing furniture. It is noteworthy that risk stratification tools (e.g. REVEAL 2.0 and ESC/ERS) used for prognostication in PAH patients do not include physical examination findings, although the REVEAL 2.0 does incorporate heart rate and systolic blood pressure, which can be easily performed by a patient at home.

While smartphones become increasingly ubiquitous in society, many individuals remain without access to the resources needed to perform VV. Particularly in rural communities, the availability of high-speed internet or mobile data networks may be insufficient, and regardless of population density, some individuals cannot afford to own or maintain connectivity for any camera-enabled device. Even with an operational video device, some patients may not feel confident in their ability to use it. This factor can be especially prominent under the circumstances of a medical visit subject to the time pressures of practicing medicine. Certain patients may even fear potential embarrassment or exposure of cognitive impairment if they are unable to launch a videoconference "in the moment" successfully. In those patients unable or unwilling to participate in VV, audio-only telephone encounters are an alternative.

ing is essential in the ambulatory assessment of PAH patients. Information collected during the interview helps in determination of functional capacity, informing suspicion for potential disease progression. Historical points collected during a telemedical visit should be similar to in-person encounters and focused on determination of functional capacity, presence of dyspnea or other symptoms at a given activity level, knowledge of PAH drug treatment, therapeutic adherence, and potential adverse effects, particularly in patients who are on continuous intravenous prostacyclin therapy. Activity assessment in patients who are spending most of their time at home can be challenging; of course, the need for physical distancing has led to increased time at home for most individuals. This effect has led to often substantial cardiopulmonary deconditioning for those who previously performed the bulk of their most physically exertional activities outdoors or otherwise removed from the home (e.g. walking or ascending stairs in workplaces, grocery stores, or other shopping environments). Notably, a recent study by Salvi et al. supported the 6MWT as feasible in the home environment using device-based applications 31 , but such tools have yet to undergo validation among individuals with PAH.

Distinction between deconditioning-related dyspnea and worsening of underlying PAH is critical yet often difficult. Information about weight gain may be important, and especially if decompensation is considered imminent, serial assessment of body weight can be highly useful.

Any available patient-acquired biometric data such as weight, blood pressure, oxygen saturation, heart rate, or cardiac rhythm tracings generated by wearable devices (e.g. Apple Watch 32, 33 ) should be incorporated, to the extent reliable. As previously noted, heart rate and blood pressure are integral elements of the REVEAL 2.0 risk prediction tool. When telemedical visits are scheduled, patients and/or their family members and caregivers may be reminded to use any available biometric devices and generally prepare for the visit as much as possible in order to maximize the objective information available to the provider, and in doing so, optimize the quality of care to the fullest extent achievable remotely.

One of the most significant challenges in the evaluation of patients with PAH during telemedical visits is assessment of functional capacity. As previously introduced, in routine clinical practice, detailed history taking focusing on the patient's activities of daily living and a formal six-minute walk test (6MWT) is the guideline-supported standard of care in the longitudinal management of PAH patients 4,6,7 and has been shown to predict long-term outcomes 34, 35 . Objective activity assessment obtainable remote to a health care facility has not been standardized among PAH patients. However, several potential options may augment the subjective assessment. The Duke Activity Status Index (DASI) was derived in 1989 to assess functional capacity in subjects undergoing cardiac exercise testing 36 . The DASI is a self-administered 12-point questionnaire intended to determine the respondent's effort tolerance based on whether he or she reports the ability to complete certain physical activities. Items chosen for inclusion in the DASI tool represent a broad range of cardiovascular stressors as well as several dimensions of personal health status (Figure 3) . Use of the DASI has been validated in patients with cardio-pulmonary diseases like HF and chronic obstructive pulmonary disease (COPD) 37, 38 .

While not yet validated for use in patients with PAH, application of the DASI or other questionnaire-type functional status measures to PAH patients warrants further exploration.

Beyond metrics based on self-report, a possible surrogate for the traditional 6MWT is the incremental shuttle walk test (ISWT), which is an exercise test that patients can perform in a self-directed fashion 39, 40 . The objective of the ISWT is to walk as long as tolerated, from start to finish of a 10-meter course and back, keeping to the speed indicated by recorded audio indicators ("beeps"). Each single beep signals the end of a shuttle, and each triple beep signals an increase in walking speed. The participant is directed to stop walking only when he or she becomes too breathless to maintain the required speed or can no longer keep up with the set pace. A progressive and maximal self-directed test, the ISWT has been validated against 6MWT results 41 , as have other smartphone-app based self-directed 6MWTs 42, 43 . The most significant concern is assurance of the safety of the patient during testing, a factor that can potentially be ameliorated by training a family member or caregiver to supervise the patient during the test. Additionally, these

tests have yet to be formally validated in the home setting. Overall, functional capacity evaluation outside of a health care setting is a critical feature of PAH management in the era of COVID-19, the optimization of which requires utilization of patient-provided history and possibly functional questionnaires, self-directed exercise testing such as the ISWT, as well as potentially novel technologies, to be discussed subsequently.

In the last few years, there has been growing evidence to support the use of patient reported outcomes (PROs) in the management of PAH. The objective of PRO use is to assess the patient's quality of life (QoL) and to involve the patient's own perspective in disease management. 'Patient perspective' is the patient's experience of PAH and its impact on him/her and caregivers, including symptomatic, intellectual, psychosocial, spiritual and goal-oriented dimen-sions of the disease and its treatment 44 . Table 1 In another study of 54 consecutive newly diagnosed patients with PAH who received first-line endothelin receptor antagonists or PDE-5i, a baseline SF-36 Physical Component Summary (PCS) score >32 was associated with a better survival rate than a score <32 (p=0.04).

Moreover, patients exhibiting a PCS score ≥38 after 16 weeks of treatment demonstrated a superior 3-year survival rate versus those who scored <38 on the PCS (p=0.016) 48 . Given the treatment-related benefits in HRQoL observed in patients with PAH, mounting evidence implicates a future role for improved HRQoL as a prognostic marker in PAH 49 . A recent study from the Pulmonary Hypertension Association Registry (PHAR) showed that PAH patients judged at high risk by COMPERA and REVEAL 2.0 risk assessment tools had greater risk of death and hospitalization, and had worse disease-specific health related quality of life, as assessed by the em-PHasis-10 and Medical Outcome Study Short Form-12 (SF-12) general physical and mental component scores 50 . Another randomized study (NCT03078907) of selexipag vs. placebo in functional class II PAH patients used accelerometry (GT9X Link, ActiGraph), along with PAH-SYMPACT to assess daily physical activity 51 .Although this study did not meet its primary endpoint, it did provide important insight into using accelerometers and PROs in assessing activity in PAH patients, As such, these findings are intriguing and suggest a potential role for PRO tools in management of PAH, telemedical or otherwise.

Many devices that individuals may own, and maintain on their persons regularly, easily obtain objective measures of physical activity, the preeminent example of which is step counting.

The essentially ubiquitous example of this is the smartphone. For example, the Apple iPhone harbors a Health app that summarizes step estimates derived from accelerometric and other embedded sensors, generated with movement of the device when carried 52 . Android-based and other smartphones offer similar options. However, the smartphone itself is one of a myriad of other "wearable" items that collect activity and other biometric information that may be linked to a smartphone or computer, devices which include not only "smart" watches or wrist-worn bands (examples of such manufacturers include FitBit, Garmin, Withings, and Polar) but also a variety of technology-enabled products 53 . Examples of other novel accessories include earphones, necklaces, hats, and even "smart shirt" garments, most of which provide some combination of biometric data such as steps taken, heart rate, and respiratory variability. Much of the available new and often pricey technology is marketed towards individuals with high physical functioning and adequate discretionary financial resources. However, in the coming years the "wearable" boom will undoubtedly result in new products, the data output from which providers can harness for the management of individuals with PAH and other chronic cardiopulmonary diseases.

Biometric data collected by personally owned devices, often even without the awareness of the wearer/user, constitute a vast untapped resource in the management of individuals with cardiovascular disease. Most health care systems currently lack the infrastructure for health care providers, nurses, and other staff to access and utilize the wealth of biometric information being stored on personal devices. To present a clinical example, consider a 40 year-old woman with chronic PAH who at baseline is managed on oral therapy and has Class II symptoms; she owns a smartphone and wears a smart bracelet (e.g. Fitbit) most of the time, which measures her steps and heart rate continuously. In March, she stopped walking her dog as regularly and avoided shopping for groceries herself because of perceived risk of SARS-CoV-2 exposure, for which reason she also rescheduled her routine follow-up visit with her PAH provider. In May she found herself with increased swelling and then breathless with dressing or cleaning dishes; later, she was hospitalized in June with syncope. It is likely that this patient's health care providers would have observed several key biometric trends over the months of decompensation, had the data from her smartphone and smart band (e.g. Fitbit) been available for review. For example, decreased step count, increased resting heart rate, decreased heart rate variability, and (if assessed/recorded) increased body weight may have developed (Figure 4 ). Slow and subtle changes in such parameters that may be imperceptible to the patient may be uncovered by automated analysis or machine learning, and significant deviations could potentially generate notifications to health providers.

The process of regular integration of such biometric mHealth data into the electronic health record of the patient's medical home is now feasible and in clinical use at certain institutions (e.g. MyChart Fitness Tracker, Epic Systems, Verona, WI). Often, biometric data are combined from various sources into a centralized interface (Table 2) . For example, the user's primary smartphone mHealth application (e.g. Apple Health, Google Fit) collects and summarizes data from internal sensor sources and may integrate with output from any other smart devices or wearables that the user has linked. With the user's permission, the mobile application specific to the patient's health system (e.g. MyChart mobile, Epic Systems, Verona, WI) can access the mHealth data and generate applicable summaries or alerts at the discretion and order of the managing health care provider. Commercial third-party, web-/app-based solutions providing interactivity between mHealth data and care providers are also available (e.g. Tholomeus®) 54 . Regular use of such mHealth data integration has been pioneered by several institutions 55 and is now undergoing rapid dissemination, with applicability to many patients with PAH.

Even an act as seemingly simple as serial assessment of body weight can be potentially optimized by emerging smart technologies. Patients who weigh themselves daily may or may not record the result, and fewer still might have the log of serial weights available at the time of an in-person or telemedical visit. Use of scales that automatically record, store (e.g. via Bluetooth bridging with the patient's smartphone), and with the process described above, link the results of serial body weight measurements can greatly improve the ability of providers to act on the data, such as via diuretic titration or guidance regarding dietary sodium or fluid intake restrictions. The same concept applies to pulse oximetric data as well. In addition, patients with PAH with comorbid arrhythmias can potentially benefit from use of cardiac rhythm monitoring devices, particularly when there is low arrhythmia awareness or if distinguishing between lowgrade ectopy and sustained arrhythmias such as atrial fibrillation is clinically challenging and management-defining. Smart watches or bands as well as external periodically activated devices (e.g. AliveCor KardiaMobile) may serve this purpose ( Table 2) . A study evaluating clinical outcomes using simultaneous digital tracking of daily physical activity, heart rate, and inhalation behavior in PAH patients treated with inhaled iloprost is underway 56 . This provocative study will provide insight into clinical outcomes, daily physical activity, and quality of life in patients with PAH and inform future research on wearable technology in this population.

Overall, while copious, data obtained from personal, consumer-marketed devices should be vetted with ongoing study to ensure adequate validity to support medical decision-making.

Even if data such as step count or distance walked are not perfectly accurate on an absolute basis, evaluation for trends may still be extremely informative on an individualized level, where each patient may serve as his or her own internal control. As previously discussed, medically validated and/or implantable monitoring devices may be complementary in certain situations.

With the advent of widespread telemedical provider visit use during the COVID-19 pandemic, in the United States (US) there existed considerable initial uncertainty regarding the reimbursement support for such service. In the first several months of pandemic-related telehealth expansion, there existed a striking differential in reimbursement and provider work credit for telephone-only vs. video visits (VVs). For example, a telephone "check-in" for an established patient (code G2012), defined as a 5 to 10 minute audio call not related to another service in the preceding 7 days nor necessitating the next-available in-person service, would receive 0.25 work relative value units (wRVU). This can be contrasted to established level 3 or level 4 VVs, which by submitting the E/M code commensurate for the complexity of medical decision-making and a telehealth modifier, garner 0.97 (99213) and 1.5 (99214) wRVU, respectively, which are currently equivalent to the in-person visits. For new patients, the discrepancy was wider still. Such structure strongly incentivized performance of VV in place of an audio-only call, and thus patients with no reliable access to VV technology could have been subject to their provider experiencing financial pressure to shorten their sessions. Consequently, even if a longer evaluation were medically indicated, the lack of a known mechanism to reimburse for the more thorough Even when the stringency of physical distancing and personal protective equipment use can be relaxed in the future, telemedical visits will likely forever remain a more prominent aspect of medicine, with an inextinguishable benefit of mitigating transportation barriers for many patients, including those with PAH and HF. Some providers and patients may consider a model in which in-person and telemedical visits are rotated or interspersed based on each patient's individual needs (including the reason for visit and anticipated magnitude of benefit of an inpersonal physical exam for the visit objective), transportation efforts, and technological device and network access and ease of utilization.

Beyond telemedical providers visits, the method in which providers and health systems receive reimbursement for review and action based on patient communication within a secure portal or mHealth biometric data continues to evolve. There is currently a billing structure for the time, effort, and expertise that providers invest in responding to and managing medical issues resulting from correspondence volunteered by patients via secure messaging portals. Codes 99421, 99422, and 99423 reimburse the provider for 5-10, 11-20, or 21 or more minutes, respectively, of time spent in evaluating and managing complaints described by established patients within secure messaging (over a 7 day period) and result in 0.25-0.80 wRVU. Such a fee structure can provide a helpful paradigm for patients who may need considerable support navigating medical concerns between provider (in-person or synchronous telemedical) visits, such as individuals with PAH. By utilizing this method of care as a billable service, providers may feel more comfortable justifying extended time, as appropriate, to evaluate and respond to patient concerns thoroughly. Patients should be notified of and consent to such billing, as with telemedical visits and in-person care. Finally, regarding mHealth data review, there is also a method in which providers may be reimbursed for "collection and interpretation of physiologic data (e.g., ECG, blood pressure…)" (code 99091) requiring a minimum of 30 minutes of time. Undoubtedly, care systems and payers must continue to evolve and adapt to provide adequate reimbursement for review of mHealth data that can be leveraged to optimize patient care.

Patients with PAH represent a unique population of individuals in whom subtle changes in functional status may associate with impactful changes in prognosis. In this era of increased physical distancing to decrease infectious risk, patients, providers, and health systems must embrace novel methods of providing medical care. Synchronous telemedical visits should thoroughly evaluate aspects of symptomatology that could signal disease progression, and augmentation with standardized assessments such as the DASI as well as various PROs may be complementary in some cases. Self-or caregiver-directed functional tests such as the ISWT or smartphone app-based 6MWT may provide objective functional assessment when presentation for a formal 6MWT is not feasible. A wealth of physiologic data, oftentimes already being collected by PAH patients' personal devices (in particular, smartphones and smart watches/bands) such as step count, heart rate, blood pressure, body weight, and/or oxygen saturation, usually remains obscured from the view of health care providers. This issue necessitates rapid evolution in health care systems coupled with patient and provider education to harness the vast source of mHealth data, in order to identify changes that could indicate disease progression and trigger therapeutic intensification, in particular among patients with PAH and other cardiovascular diseases.

Dr. Sahay reports personal fees and non-financial support from Bayer Pharmaceuticals, personal fees and non-financial support from United Therapeutics, personal fees and non-financial support from Actelion Pharmaceuticals, grant from ACCP CHEST. Personal fees from Liquidia, Gossamer and Altavant sciences.

Dr. Farber reports personal fees from Actelion, personal fees from Bayer, personal fees from United Therapeutics (Arena), personal fees from Boehringer-Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Acceleron, personal fees from Altavant, outside the sub- Is the patient able to Figure 4 : Conceptual diagram depicting the potential for technology-enabled devices to track and identify disturbances in biometric data prior to a decompensated state of cardiovascular disease. Table 2 . Examples of biometric parameters used in mHealth and potential consumer-marketed data sources for each. The authors do not endorse or promote any specific brand or product.

Potential sources of data Heart rate (HR): Average resting, min., max., variability  Smart watch or band with photoplethysmographic sensor  Other "wearable" device or clothing (e.g. ring, pendant, shirt, chest band, earphones)  Manual entry from unlinked BP cuff or pulse oximeter Blood pressure (BP)  Smart/linked BP cuff, wrist or arm  Manual entry from unlinked BP cuff Step count; Distance ambulated  Smart watch or band acquiring accelerometric and/or GPS data  Smartphone (carried for sufficient duration of day / period of physical activity)  Other "wearable" device or clothing (e.g. ring, pendant, shirt, earphones)  Manual entry from unlinked pedometer / step counter Oxygen saturation  Smart pulse oximeter  Manual entry from unlinked pulse oximeter Sleep pattern  Smart watch, band, or other "wearable" worn during sleep Cardiac rhythm  Smart watch or band with appropriate capability (e.g. Apple Watch)  Non-worn / intermittently applied smart device (e.g.

AliveCor KardiaMobile)

Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review

American Telemedicine Association (ATA)

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies

ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension

Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report

Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report

Virtual echocardiography screening tool to differentiate hemodynamic profiles in pulmonary hypertension

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care

Disparities in case frequency and mortality of coronavirus disease 2019 (COVID-19) among various states in the United States

Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?

Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?

Structured telephone support or telemonitoring programmes for patients with chronic heart failure

Telemonitoring in patients with heart failure

Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry. A Candidate Clinical Endpoint

Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics

Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations

Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls

Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices

Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor

Reveal LINQ[TM] Heart Failure (LINQ HF) NCT02758301. U.S. National Library of Medicine

Virtual visits versus in-person vistis and appointment no-show rates

Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation

Wearable Devices for Cardiac Rhythm Diagnosis and Management

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial

The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension

A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index)

Health-Related Quality of Life, Functional Status, and Cardiac Event-Free Survival in Patients With Heart Failure

Criterion validity of the Duke Activity Status Index for assessing functional capacity in patients with chronic obstructive pulmonary disease

Development of a shuttle walking test of disability in patients with chronic airways obstruction

The incremental shuttle walking test in elderly people with chronic airflow limitation

The incremental shuttle walk test in pulmonary hypertension

Diagnostic Accuracy of a Smartphone based Six-Minute Walk Test

Accuracy and Usability of a Self-Administered 6-Minute Walk Test Smartphone Application

The importance of patient perspectives in pulmonary hypertension

Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patientreported outcome instrument for PAH

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY

Quality of life as a prognostic marker in pulmonary arterial hypertension

Pulmonary arterial hypertension: the burden of disease and impact on quality of life

Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension: the Pulmonary Hypertension Association Registry (PHAR)

Assessing daily life physical activity by actigraphy in pulmonary arterial hypertension: insights from the randomized controlled study wtih selexipag (TRACE)

A more personal health app

Wearable tech media and research

Telehealth in chronic disease management and the role of the Internet-of-Medical-Things: the Tholomeus® experience

Novant makes the wearable connection

Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study

COVID-19 emergency declaration blanket waivers for health care providers

CMS hikes telephone visit payments during pandemic

929805?nlid=135352_5653&src=wnl_newsalrt_ dai-ly_200501_MSCPEDIT&uac=283639DV&impID=2367153&faf=1&fbclid=IwAR3uOs hkqVzXW97TA8qgwUr9pzhJMa3pfPomgOHWG_2g264NblgB3_HZdrE

Telehealth Bills Pile Up; Spike Starts to Slide

New Telehealth Bill; Remote COVID Care Outcomes

take care of self, i.e. eating, dressing, bathing or using the toilet?

do moderate work around the house, such as vacuuming, sweeping floors, or carrying in groceries

bowling, dancing, doubles tennis, or throwing a baseball or football? 12. participate in strenuous sports like swimming, singles tennis, football, basketball or skiing?

The highest score is 58.2, which corresponds to 9.89 metabolic equivalents (METs)

Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LPH: Living with Pulmonary Hypertension questionnaire

CHFQ: Chronic Heart Failure Questionnaire; emPHasis-10: 10-question survey proposed by the Pulmonary Hypertension Association UK

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension

Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire

Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients

Development and testing of a new measure of health status for clinical trials in heart failure

emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension

Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire: a new patientreported outcome instrument for PAH